Volume 1.22 | Aug 14

Protection against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
Researchers report that the Plasmodium falciparum sporozoites (PfSPZ) vaccine was safe and well-tolerated when administered four to six times intravenously (IV) to 40 adults. PfSPZ-specific antibody and T cell responses were dose-dependent. These data indicate that there is a dose-dependent immunological threshold for establishing high-level protection against malaria that can be achieved by IV administration of a vaccine that is safe and meets regulatory standards. [Science]Abstract|Press Release